Products English_20120222

Home Products


the picture of the article


Common Name: Recombinant Human Erythropoietin Injection

Erythropoietin is a glycoprotein that excreted in the kidney and stimulates the proliferation and differentiation of committed erythroid progenitors in the bone marrow. It can increase the production of Red Blood Cells.

Indications: Anemia associated with renal failure: including patients on hemodialysis (HD) and non-dialysis (ND), peri-operative red blood cell mobilization, and anemia associated with chemotherapy in cancer patients with non-myeloid malignancies. EPIAO is firstly approved for the treatment of peri-operative red blood cell mobilization and anemia associated with chemotherapy in cancer patients in China.

10,000IU/vial is the unique specification developed by 3SBio, which could be used conveniently in all above-mentioned indications. In 2011, the SFDA approved a 36,000 IU formulation for chemotherapy indications.



Common Name:Recombinant human thrombopoietin injection

Thrombopoietin (TPO) is an endogenous cytokine which can stimulate the growth and differentiation of megakaryocyte. It can increase the quantity of platelet through its stimulative function on each growth phase of megalokaryocyte including proliferation of pro-cell, development and maturation of polyploidy megalokaryocyte. Recombinant human thrombopoietin(rhTPO)is a full-length glycosylated thrombopoietin which is expressed in China Hamster Ovary (CHO) cell line via recombinant genetic technology. It has similar pharmacological function on increasing the quantity of platelet with endogenous thrombopoietin.

Indication :

TPIAO is suitable for the thrombocytopenia associated with chemotherapy in cancer patients with solid tumours. TPIAO therapy is recommended to patients with the platelet level lower than 50×109/L or physicians considered it necessary to increase the level of plateletTPIAO is developed by Sunshine itself as National Class I New Drug, which is the first recombinant human thrombopoietin approved launched on the market all over the world. rhTPO is considered to another landmark of biopharmaceuticals after rhEPO and rhG/GM-CSF.

In 2011, the SFDA approved TPIAO for the treatment of immune thrombocytopenia (ITP).  



Common Name: Recombinant Interferon a-2a Lyophilized Powder & Injectable solution.
Recombinant Human Interferon a2a exerts broad-spectrum antitumor, antiviral and immuno-regulatory activities. By binding to specific receptors on the cell surface, it can induce the production of antiviral protein that can inhibit the replication of viruses in host cells, improve the immune response by enhancing the phagocytose of phagocytes, cytotoxicity of lymphocyte and the function of natural killer cells.

1.Lymphatic or haemopoietic tumor: Hairy cell leukemia, multiple myeloma, non-Hodgkin’s lymphoma, chronic myeloid leukemia
2.Viral disease:
Chronic hepatitis B patients with indicators such as positive HBV-DNA, positive DNA polymerase and positive HBeAg;
Acute and chronic hepatitis C patients with indicators such as positive HCV antibody, elevated serum alanine aminotransferase (ALT) and without compensated liver disease (Child class A)
condylomata acuminata



Common Name: Recombinant Human Interleukin-2 Lyophilized Powder
INLEUSIN is an important lymphokine, for the proliferation of cytotoxic T cell, natural killer cell and lymphokine-activated killer cell and enhancing their cytopathic activity. It also accelerates the lymphocyte excreting antibody and interferon, exerting antiviral, anti-tumor activity and enhancing human immuno-regulation activity.

INLEUSIN mainly is indicated for treatment of metastatic renal cell carcinoma (RCC), malignant melanoma and control of carcinomatous hydrothorax and hydroperitoneum.


IV Iron Sucrose

IV Iron Sucrose , an intravenously administered prescription drug that is designed to treat anemia associated with iron deficiency, is indicated for patients with end-stage renal disease requiring iron replacement therapy. We in-licensed five-year exclusive PRC distribution rights for this product from Shenyang Borui Pharmaceutical Company Limited in May 2006. IV Iron Sucrose was launched in China in 2005, and we believe it will be complementary to our EPIAO franchise.